Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.

Clinical pharmacokinetics - 1 Jan 2006

Djebli Nassim, Rousseau Annick, Hoizey Guillaume, Rerolle Jean-Philippe, Toupance Olivier, Le Meur Yann, Marquet Pierre

Abstract excerpt

OBJECTIVES: The objectives of the present study were: (i) to analyse the population pharmacokinetics of sirolimus in renal transplant recipients co-administered mycophenolate mofetil, but no calcineurin inhibitor over the first 3 months post-transplantation and study the influence of different po...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Clinical Trials as Topic
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Graft Rejection

Share to Immunosuppressive Agents

Share to Kidney Transplantation

Share to Mycophenolic Acid

Share to Sirolimus

Source

Identifiers

PMID: 17048977
DOI: 10.2165/00003088-200645110-00007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17048977-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.PMID 17048977Read ↗

Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.Semantic proximity Read ↗

Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.Semantic proximity Read ↗

CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.Semantic proximity Read ↗

Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.Semantic proximity Read ↗

A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators.Semantic proximity Read ↗

Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients.Semantic proximity Read ↗

Use of Pharmacogenetics to Optimize Immunosuppressant Therapy in Kidney-Transplanted PatientsSemantic proximity Read ↗

A population pharmacokinetic model for early follow-up dosing of tacrolimus in Tunisian kidney transplant recipients.Semantic proximity Read ↗

Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.Semantic proximity Read ↗

Population pharmacokinetic analyses of tacrolimus in non-transplant patients: a systematic review.Semantic proximity Read ↗

Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation.Semantic proximity Read ↗

Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.